Mission-Driven Dementia Funding with DDF's Jonathan Behr
Business Of Biotech
Challenges and Successes in Developing Disease-Modifying Drugs for Cognitive Disorders
The chapter delves into the obstacles and achievements in creating disease-modifying medications for cognitive disorders such as Alzheimer's disease. It reflects on the historical disparity in drug approvals between areas like oncology and cognitive disorders, recent advancements in drug approvals, and the impact on drug development perceptions. The conversation emphasizes the significance of balancing short-term factors like investment appeal with long-term considerations for patient needs and the drug development pipeline.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
